Black Diamond Therapeutics Q2 net loss $20M; cash $89.5M; BDTX-1535 shows initial clinical activity

Black Diamond Therapeutics, Inc.

2023-Q2 EPS reported -$1.09

Net loss $20.0M for Q2 2023 vs $23.2M for Q2 2022; R&D expenses $13.2M down from $16.2M.
Cash, equivalents & investments $89.5M as of June 30, 2023; plus $75M gross from July follow-on offering extends runway into H1 2025.
BDTX-1535 Phase 1 dose-escalation showed confirmed partial responses in 5 of 12 evaluable NSCLC patients; expansion cohorts initiated July 2023.
Phase 1 trial for BDTX-4933 (BRAF/RAS inhibitor) initiated in Q2 2023; GBM dose-escalation update expected Q4 2023.
FDA meeting planned in Q4 2023 to discuss accelerated approval pathway for BDTX-1535 in NSCLC.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Black Diamond Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Black Diamond Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001701541-23-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.